Related Experiment Video

Updated: Feb 1, 2026

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

13.3K

In Vitro Activity of Omadacycline against Chlamydia pneumoniae

Stephan A Kohlhoff1, Natalia Huerta2, Margaret R Hammerschlag2

  • 1Department of Pediatrics, Division of Pediatric Infectious Diseases, State University of New York Downstate Medical Center, Brooklyn, New York, USA stephan.kohlhoff@downstate.edu.

Antimicrobial Agents and Chemotherapy
|December 5, 2018
PubMed

Insights

Omadacycline demonstrated potent in vitro activity against Chlamydia pneumoniae, showing a low minimum inhibitory concentration. This novel antibiotic may offer a new treatment option for C. pneumoniae infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Chlamydia pneumoniae is a significant cause of respiratory infections.
  • Antibiotic resistance is a growing concern for treating C. pneumoniae.
  • Evaluating new antibiotics for C. pneumoniae is crucial.

Purpose of the Study:

  • To assess the in vitro antibacterial activity of omadacycline against Chlamydia pneumoniae.
  • To compare omadacycline's efficacy with established antibiotics.

Main Methods:

  • In vitro testing of five antibiotics: omadacycline, azithromycin, doxycycline, moxifloxacin, and levofloxacin.
  • Testing was performed against 15 clinical isolates of Chlamydia pneumoniae.
  • Minimum Inhibitory Concentration (MIC90) was determined for each antibiotic.

Main Results:

  • Omadacycline exhibited a potent MIC90 of 0.25 μg/ml against C. pneumoniae isolates.
  • The range of omadacycline's MIC was 0.03 to 0.5 μg/ml.
  • Comparative data against other tested antibiotics were generated (details not provided in abstract).

Conclusions:

  • Omadacycline displays significant in vitro activity against Chlamydia pneumoniae.
  • Omadacycline represents a promising candidate for further development in treating C. pneumoniae infections.
Keywords:
Chlamydia pneumoniaeomadacyclinetetracyclines

More Related Videos

Using Fluorescent Proteins to Visualize and Quantitate Chlamydia Vacuole Growth Dynamics in Living Cells07:42

Using Fluorescent Proteins to Visualize and Quantitate Chlamydia Vacuole Growth Dynamics in Living Cells

Published on: October 13, 2015

7.9K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.2K

Related Concept Videos

Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic...
511
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
895
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.9K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
816
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.5K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
862